Jan M. Foote, DNP, ARNP, CPNP Pediatric Nurse Practitioner Blank Children's Endocrinology Clinic Des Moines, IA Clinical Associate Professor The University of Iowa Iowa City, IA
Jennifer S. Cook, MD Pediatric Endocrinologist Blank Children's Endocrinology Clinic Des Moines, IA
CME: 0.75 credits
NAPNAP CE: 0.75 credits Medium
Approximately 10,000 to 15,000 children in the United States have problems with growth. Recombinant human growth hormone (GH) has been approved by the FDA for growth disorders in children. Though the FDA has specific indications for GH therapy, growth disorders are typically marked by either growth failure or short stature defined as 2 standard deviations or more below the normal mean for age and gender. GH is used for the treatment of a variety of pediatric disorders associated with growth retardation and metabolic dysfunction. Early recognition, accurate diagnosis, and appropriate initiation of GH treatment for children with growth disorders can improve growth rate, metabolic effects (bone mineral density and body composition), and quality of life. The aim of this interactive newsletter is to address strategies for improving the diagnosis and management of pediatric growth disorders, ultimately improving patient outcomes.
This activity is jointly provided by the National Association of Pediatric Nurse Practitioners, Penn State College of Medicine, and MCM Education.
This activity is designed for pediatricians, pediatric nurse practitioners, and other pediatric clinicians involved in the diagnosis and treatment of pediatric patients with growth disorders.
Upon completion of this educational activity, the participant should be able to:
Discuss the steps in accurately diagnosing children with growth hormone deficiency and other growth disorders.
Identify normal and abnormal growth rates and criteria for evaluation and referral to pediatric endocrinology.
List the pediatric indications for which growth hormone is approved for treatment.
Describe the efficacy and safety of growth hormone therapy for pediatric growth disorders.
Describe clinical advances in growth hormone delivery systems that improve their ease-of-use and may support better patient adherence to treatment.
Jennifer Cook, MD has nothing to disclose.
Jan Foote, DNP, ARNP, CPNP has disclosed the following:
Speakers Bureau: Abbvie, Genentech, Novo Nordisk, Pediatric Endocrinology Nursing Society
Penn State faculty and staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
It is the policy of the National Association of Pediatric Nurse Practitioners and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
This program is accredited for 0.75 NAPNAP CE contact hours per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 45 minutes to complete.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5725-15-T. Commercial Support Statements
Supported by an independent educational grant from Novo Nordisk.
Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to allow access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
After you have finished reviewing the activity, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
©2015, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the National Association of Pediatric Nurse Practitioners, Penn State College of Medicine, or Novo Nordisk. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.